Related Experiment Videos
CDKN2A gene inactivation in epithelial sporadic ovarian cancer
D Niederacher1, H Y Yan, H X An
1Department of Obstetrics and Gynaecology, Heinrich-Heine-University, Düsseldorf, Germany.
Abstract:
The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16. Inactivation of the CDKN2A gene could lead to uncontrolled cell growth. In order to determine the role of CDKN2A in the development of sporadic ovarian cancer, loss of heterozygosity at 9p21-22, homozygous deletion, mutation and methylation status of the CDKN2A gene as well as CDKN2A expression were examined in a panel of serous papillary ovarian cancer. The frequency of loss of heterozygosity (LOH) for one or more informative markers at 9p21-22 was 65% (15/23). The most common deleted region was located between interferon (IFN)-alpha and D9S171. Homozygous deletions and mutations of the CDKN2A gene were not found. There was no evidence of methylation in exon 1, but methylation in exon 2 of CDKN2A gene was found in 26% (6/23). Absence of CDKN2A gene expression was shown in 27% (6/22) at mRNA level and 21% (4/19) at protein level. These data suggest that the CDKN2A gene is involved in the tumorigenesis of ovarian cancer, but the mechanisms of CDKN2A gene inactivation in serous papillary ovarian cancer remains unclear.
Insights
The CDKN2A tumor suppressor gene is frequently altered in sporadic ovarian cancers, with loss of heterozygosity and methylation observed. These changes may contribute to uncontrolled cell growth in ovarian cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The CDKN2A gene, encoding the p16 protein, is a crucial tumor suppressor.
- Inactivation of CDKN2A can lead to uncontrolled cell proliferation.
- Its role in sporadic ovarian cancer warrants investigation.
Purpose of the Study:
- To investigate the role of the CDKN2A gene in sporadic ovarian cancer development.
- To examine alterations including loss of heterozygosity, deletion, mutation, and methylation.
- To assess CDKN2A gene expression at mRNA and protein levels.
Main Methods:
- Analysis of loss of heterozygosity at 9p21-22 in ovarian cancer samples.
- Assessment of homozygous deletions, mutations, and methylation status of the CDKN2A gene.
- Evaluation of CDKN2A mRNA and protein expression.
Main Results:
- Loss of heterozygosity (LOH) at 9p21-22 occurred in 65% of cases.
- No homozygous deletions or mutations in the CDKN2A gene were detected.
- Methylation in exon 2 was found in 26% of samples, and absent expression in 27% (mRNA) and 21% (protein).
Conclusions:
- The CDKN2A gene is implicated in the tumorigenesis of ovarian cancer.
- Mechanisms of CDKN2A inactivation in serous papillary ovarian cancer require further elucidation.
- Alterations like LOH and methylation suggest CDKN2A's involvement.